Role of the Microbiota in Colorectal Cancer: Updates on Microbial Associations and Therapeutic Implications

BioResearch Open Access

Volumn 5, Issue 1, 2016, Pages 279-288

  Coleman, Olivia I ^a   Nunes, Tiago ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

colorectal cancer; intestinal microbiota; tumorigenesis

Indexed keywords

CARCINOGENESIS; COLON FLORA; COLORECTAL CANCER; COMMUNITY STRUCTURE; DISEASE COURSE; GENOTOXICITY; HUMAN; INTESTINE FLORA; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

EID: 85008262667     PISSN: None     EISSN: 21647860     Source Type: Journal    
DOI: 10.1089/biores.2016.0028     Document Type: Review

References (98)

1. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. Cancer J Clin. 2014;64:104-117.
2. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. Cancer J Clin. 2014;64:9-29.
3. Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103:117-128.
4. Lang K, Lines LM, Lee DW, et al. Lifetime and treatment-phase costs associated with colorectal cancer: evidence from SEER-Medicare data. Clin Gastroenterol Hepatol. 2009;7:198-204.
5. Fleming M, Ravula S, Tatishchev SF, et al. Colorectal carcinoma: pathologic aspects. J Gastrointest Oncol. 2012;3:153-173.
6. Ponz de Leon M, Percesepe A. Pathogenesis of colorectal cancer. Digest Liver Dis. 2000;32:807-821.
7. Centelles JJ. General aspects of colorectal cancer. ISRN Oncol. 2012;2012:139268.
8. Jass JR. Pathogenesis of colorectal cancer. Surg Clin North Am. 2002;82:891-904.
9. O'Keefe SJD, Chung D, Mahmoud N, et al. Why do African Americans get more colon cancer than native Africans? J Nutr. 2007;137:175s-182s.
10. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis. C Oncogene 2006;25:3834-3847.
11. Guerrieri F, Belloni L, Pediconi N, et al. Molecular mechanisms of HBV-associated hepatocarcinogenesis. Semin Liver Dis. 2013;33:147-156.
12. McMahon BJ. Chronic hepatitis B virus infection. Med Clin North Am. 2014;98:39-54.
13. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325: 1127-1131.
14. Stolte M, Meining A. Helicobacter pylori and Gastric Cancer. Oncologist. 1998;3:124-128.
15. Wroblewski LE, Peek RM, Jr., Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev. 2010;23:713-739.
16. Hardbower DM, de Sablet T, Chaturvedi R, et al. Chronic inflammation and oxidative stress: the smoking gun for Helicobacter pylori-induced gastric cancer? Gut Microbes. 2013;4:475-481.
17. Koeppel M, Garcia-Alcalde F, Glowinski F, et al. Helicobacter pylori infection causes characteristic DNA damage patterns in human cells. Cell Rep. 2015;11:1703-1713.
18. Wroblewski LE, Peek RM, Jr. Helicobacter pylori in gastric carcinogenesis: mechanisms. Gastroenterol Clin North Am. 2013;42:285-298.
19. Wang X, Allen TD, May RJ, et al. Enterococcus faecalis induces aneuploidy and tetraploidy in colonic epithelial cells through a bystander effect. Cancer Res. 2008;68:9909-9917.
20. Wang X, Huycke MM. Extracellular superoxide production by Enterococcus faecalis promotes chromosomal instability in mammalian cells. Gastroenterology. 2007;132:551-561.
21. Balish E, Warner T. Enterococcus faecalis induces inflammatory bowel disease in interleukin-10 knockout mice. Am J Pathol. 2002;160:2253-2257.
22. Cuevas-Ramos G, Petit CR, Marcq I, et al. Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci U S A. 2010;107:11537-11542.
23. Arthur JC, Perez-Chanona E, Muhlbauer M, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012;338:120-123.
24. Buc E, Dubois D, Sauvanet P, et al. High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PloS One. 2013;8:e56964.
25. Goodwin AC, Destefano Shields CE, Wu S, et al. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proc Natl Acad Sci U S A. 2011;108:15354-15359.
26. Wu S, Rhee KJ, Albesiano E, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med. 2009;15:1016-1022.
27. Kim SC, Tonkonogy SL, Albright CA, et al. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology. 2005;128:891-906.
28. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science. 2007;317:124-127.
29. Su LK, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science. 1992;256:668-670.
30. Uronis JM, Muhlbauer M, Herfarth HH, et al. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PloS One. 2009;4:e6026.
31. Newman JV, Kosaka T, Sheppard BJ, et al. Bacterial infection promotes colon tumorigenesis in Apc(Min/+) mice. J Infect Dis. 2001;184:227-230.
32. Kado S, Uchida K, Funabashi H, et al. Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor beta chain and p53 double-knockout mice. Cancer Res. 2001;61:2395-2398.
33. Chu FF, Esworthy RS, Chu PG, et al. Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. Cancer Res. 2004;64:962-968.
34. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118:285-296.
35. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749-759.
36. Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317:121-124.
37. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 2008;14:109-119.
38. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nature reviews. Cancer. 2004;4:97-105.
39. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007;7:41-51.
40. Kortylewski M, Yu H. Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol. 2008;20:228-233.
41. Huycke MM, Abrams V, Moore DR. Enterococcus faecalis produces extracellular superoxide and hydrogen peroxide that damages colonic epithelial cell DNA. Carcinogenesis. 2002;23:529-536.
42. Erdman SE, Poutahidis T, Tomczak M, et al. CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. Am J Pathol. 2003;162:691-702.
43. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006;6:836-848.
44. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107-1111.
45. Marchesi JR, Dutilh BE, Hall N, et al. Towards the human colorectal cancer microbiome. PloS One. 2011;6:e20447.
46. Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012;22:292-298.
47. Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012;22:299-306.
48. Tahara T, Yamamoto E, Suzuki H, et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res. 2014;74:1311-1318.
49. Mima K, Sukawa Y, Nishihara R, et al. Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. JAMA Oncol. 2015;1:653-661.
50. Wei Z, Cao S, Liu S, et al. Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients' survival? A pilot study on relevant mechanism. Oncotarget. 2016;7:46158-46172.
51. Sansonetti PJ. War and peace at mucosal surfaces. Nat Rev Immunol. 2004;4:953-964.
52. Corfield AP, Myerscough N, Longman R, et al. Mucins and mucosal protection in the gastrointestinal tract: new prospects for mucins in the pathology of gastrointestinal disease. Gut. 2000;47:589-594.
53. Bordonaro M, Lazarova DL, Sartorelli AC. Butyrate and Wnt signaling: a possible solution to the puzzle of dietary fiber and colon cancer risk? Cell Cycle. 2008;7:1178-1183.
54. Zackular JP, Baxter NT, Iverson KD, et al. The gut microbiome modulates colon tumorigenesis. Mbio. 2013;4.
55. Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14:207-215.
56. Li Y, Kundu P, Seow SW, et al. Gut microbiota accelerate tumor growth via c-jun and STAT3 phosphorylation in APCMin/+ mice. Carcinogenesis. 2012;33:1231-1238.
57. Couturier-Maillard A, Secher T, Rehman A, et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J Clin Invest. 2013;123:700-711.
58. Tjalsma H, Boleij A, Marchesi JR, et al. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol. 2012;10:575-582.
59. Housseau F, Sears CL. Enterotoxigenic Bacteroides fragilis (ETBF)-mediated colitis in Min (Apc+/-) mice: a human commensal-based murine model of colon carcinogenesis. Cell Cycle. 2010;9:3-5.
60. Ahmed S, Macfarlane GT, Fite A, et al. Mucosa-associated bacterial diversity in relation to human terminal ileum and colonic biopsy samples. Appl Environ Microbiol. 2007;73:7435-7442.
61. Shen XJ, Rawls JF, Randall T, et al. Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas. Gut Microbes. 2010;1:138-147.
62. Boleij A, Muytjens CM, Bukhari SI, et al. Novel clues on the specific association of Streptococcus gallolyticus subsp gallolyticus with colorectal cancer. J Infect Dis. 2011;203:1101-1109.
63. Boleij A, van Gelder MM, Swinkels DW, et al. Clinical Importance of Streptococcus gallolyticus infection among colorectal cancer patients: systematic review and meta-analysis. Clin Infect Dis. 2011;53: 870-878.
64. Heerdt BG, Houston MA, Augenlicht LH. Short-chain fatty acid-initiated cell cycle arrest and apoptosis of colonic epithelial cells is linked to mitochondrial function. Cell Growth Differ. 1997;8:523-532.
65. Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009;461:1282-1286.
66. Pitt JM, Vétizou M, Waldschmitt N, et al. Fine-Tuning Cancer Immunotherapy: optimizing the Gut Microbiome. Cancer Res. 2016;76:4602-4607.
67. West NR, Powrie F. Immunotherapy not working? check your microbiota. Cancer Cell. 2015;28:687-689.
68. Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350:1084-1089.
69. Vetizou M, Pitt JM, Daillere R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350:1079-1084.
70. Candela M, Turroni S, Biagi E, et al. Inflammation and colorectal cancer, when microbiota-host mutualism breaks. World J Gastroenterol. 2014;20:908-922.
71. Cougnoux A, Delmas J, Gibold L, et al. Small-molecule inhibitors prevent the genotoxic and protumoural effects induced by colibactin-producing bacteria. Gut. 2016;65:278-285.
72. Zsivkovits M, Fekadu K, Sontag G, et al. Prevention of heterocyclic amineinduced DNA damage in colon and liver of rats by different lactobacillus strains. Carcinogenesis. 2003;24:1913-1918.
73. Rowland IR, Rumney CJ, Coutts JT, et al. Effect of Bifidobacterium longum and inulin on gut bacterial metabolism and carcinogen-induced aberrant crypt foci in rats. Carcinogenesis. 1998;19:281-285.
74. Pool-Zobel BL, Munzner R, Holzapfel WH. Antigenotoxic properties of lactic acid bacteria in the S. typhimurium mutagenicity assay. Nutr Cancer. 1993;20:261-270.
75. Ayebo AD, Shahani KM, Dam R. Antitumor component(s) of yogurt: fractionation. J Dairy Sci. 1981;64:2318-2323.
76. Reddy GV, Shahani KM, Banerjee MR. Inhibitory effect of yogurt on Ehrlich Ascites tumor-cell proliferation. J Natl Cancer Inst. 1973;50:815-817.
77. Pool-Zobel BL, Bertram B, Knoll M, et al. Antigenotoxic properties of lactic acid bacteria in vivo in the gastrointestinal tract of rats. Nutr Cancer. 1993;20:271-281.
78. Pool-Zobel BL, Neudecker C, Domizlaff I, et al. Lactobacillus- and bifidobacterium-mediated antigenotoxicity in the colon of rats. Nutr Cancer. 1996;26:365-380.
79. Goldin BR, Gorbach SL. Effect of Lactobacillus acidophilus dietary supplements on 1, 2-dimethylhydrazine dihydrochloride-induced intestinal cancer in rats. J Natl Cancer Inst. 1980;64:263-265.
80. Goldin BR, Gualtieri LJ, Moore RP. The effect of Lactobacillus GG on the initiation and promotion of DMH-induced intestinal tumors in the rat. Nutr Cancer. 1996;25:197-204.
81. Reddy BS, Rivenson A. Inhibitory effect of Bifidobacterium longum on colon, mammary, and liver carcinogenesis induced by 2-amino-3- methylimidazo[4, 5-f]quinoline, a food mutagen. Cancer Res. 1993;53: 3914-3918.
82. Rowland IR, Bearne CA, Fischer R, et al. The effect of lactulose on DNA damage induced by DMH in the colon of human flora-associated rats. Nutr Cancer. 1996;26:37-47.
83. AmbalamP, Raman M, Purama RK, et al. Probiotics, prebiotics and colorectal cancer prevention. Best Pract Res Clin Gastroenterol. 2016;30:119-131.
84. Zeller G, Tap J, Voigt AY, et al. Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol Syst Biol. 2014;10:766.
85. Zackular JP, Rogers MA, Ruffin MTt, et al. The human gut microbiome as a screening tool for colorectal cancer. Cancer Prev Res. 2014;7:1112-1121.
86. Dejea CM, Wick EC, Hechenbleikner EM, et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci U S A. 2014;111:18321-18326.
87. Chen W, Liu F, Ling Z, et al. Human intestinal lumen and mucosaassociated microbiota in patients with colorectal cancer. PloS One. 2012;7:e39743.
88. Wu N, Yang X, Zhang R, et al. Dysbiosis signature of fecal microbiota in colorectal cancer patients. Microb Ecol. 2013;66:462-470.
89. Klein RS, Recco RA, Catalano MT, et al. Association of Streptococcus bovis with carcinoma of the colon. N Engl J Med. 1977;297:800-802.
90. Seder CW, Kramer M, Long G, et al. Clostridium septicum aortitis: report of two cases and review of the literature. J Vasc Surg. 2009;49:1304-1309.
91. Toprak NU, Yagci A, Gulluoglu BM, et al. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. Clin Microbiol Infect. 2006;12:782-786.
92. Barthold SW, Jonas AM. Morphogenesis of early 1, 2-dimethylhydrazineinduced lesions and latent period reduction of colon carcinogenesis in mice by a variant of Citrobacter freundii. Cancer Res. 1977;37:4352-4360.
93. Balamurugan R, Rajendiran E, George S, et al. Real-time polymerase chain reaction quantification of specific butyrate-producing bacteria, Desulfovibrio and Enterococcus faecalis in the feces of patients with colorectal cancer. J Gastroenterol Hepatol. 2008;23(8 Pt 1):1298-1303.
94. Martin HM, Campbell BJ, Hart CA, et al. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology. 2004;127:80-93.
95. Bonnet M, Buc E, Sauvanet P, et al. Colonization of the human gut by E. coli and colorectal cancer risk. Clin Cancer Res. 2014;20:859-867.
96. Nagamine CM, Sohn JJ, Rickman BH, et al. Helicobacter hepaticus infection promotes colon tumorigenesis in the BALB/c-Rag2(-/-) Apc(Min/+) mouse. Infect Immun. 2008;76:2758-2766.
97. Maggio-Price L, Treuting P, Zeng WP, et al. Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice. Cancer Res. 2006;66:828-838.
98. Hale LP, Perera D, Gottfried MR, et al. Neonatal co-infection with helicobacter species markedly accelerates the development of inflammation-associated colonic neoplasia in IL-10(-/-) mice. Helicobacter. 2007;12:598-604.